Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81730 | 0.90 | SLC22A2 (0.40) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17005288 | 0.87 | TOP1 (0.37) | PDE9AEGLN1JAK2JAK1 | |
| SCHEMBL83148 | 0.80 | SLC22A2 (0.42) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL10290021 | 0.78 | TOP1 (0.37) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL80768 | 0.78 | SLC22A2 (0.41) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL82276 | 0.76 | SLC22A2 (0.43) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL82244 | 0.76 | ALDH1A1 (0.41) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19138024 | 0.76 | SLC22A2 (0.40) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL83291 | 0.75 | MEN1 (0.44) | SLC22A2CYP3A4TMEM97ABCG2MEN1 | |
| SCHEMBL2679793 | 0.75 | SLC22A2 (0.42) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PDE9A 4855/4885EGLN1 2129/4885KIT 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.